vTv Therapeutics (VTVT) Income towards Parent Company (2014 - 2026)

vTv Therapeutics has disclosed Income towards Parent Company across 13 years of filings, most recently posting -$13.1 million for Q2 2026.

• In Q2 2026, Income towards Parent Company fell 76.88% year-over-year to -$13.1 million; the TTM figure through Jun 2026 stood at -$6.4 million (up 73.18% YoY), while the FY2025 annual figure was -$31.1 million, down 36.89% from the prior year.
• Income towards Parent Company came in at -$13.1 million for Q2 2026 at vTv Therapeutics, down from $24.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $24.1 million in Q1 2026 to a low of -$13.1 million in Q2 2026.
• Average Income towards Parent Company over 5 years is -$5.2 million, with a median of -$6.2 million recorded in 2022.
• Year-over-year, Income towards Parent Company plunged 386.44% in 2022 and surged 488.19% in 2026.
• Over 5 years, Income towards Parent Company stood at -$6.1 million in 2022, then advanced by 27.08% to -$4.4 million in 2023, then rose by 0.09% to -$4.4 million in 2024, then plunged by 60.87% to -$7.1 million in 2025, then plunged by 82.88% to -$13.1 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$13.1 million in Q2 2026, $24.1 million in Q1 2026, and -$7.1 million in Q4 2025.